Quest Diagnostics Incorporated (DGX) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $194.16. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of DGX = $305.38 (+57.3% from the current price, the stock appears undervalued). Analyst consensus target is DGX = $215 (+10.8% upside).
Valuation: DGX trades at a trailing Price-to-Earnings (P/E) of 22.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.81.
Financials: revenue is $11.0B, +4%/yr average growth. Net income is $992M, growing at +2.1%/yr. Net profit margin is 9% (thin). Gross margin is 31.9% (-2.8 pp trend).
Balance sheet: total debt is $6.9B against $7.2B equity (Debt-to-Equity (D/E) ratio 0.96, moderate). Current ratio is 1.04 (adequate). Debt-to-assets is 42.6%. Total assets: $16.2B.
Analyst outlook: 13 / 34 analysts rate DGX as buy (38%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 44/100 (Partial), Growth 45/100 (Partial), Past 100/100 (Pass), Health 50/100 (Partial), Moat 61/100 (Partial), Future 40/100 (Partial), Income 45/100 (Partial).
